Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study ( <scp>TOPGAN</scp> 2021‐01)-Reference-Cited by-同舟云学术

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study ( TOPGAN 2021‐01)

Published:2022-11-21 Issue:2 Volume:14 Page:168-176
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Uematsu Shinya¹^ORCID,Kitazono Satoru²,Tanaka Hisashi³^ORCID,Saito Ryota⁴,Kawashima Yosuke⁵,Ohyanagi Fumiyoshi⁶,Tozuka Takehiro⁷^ORCID,Ryosuke Tsugitomi²,Sakatani Toshio⁸,Horiike Atsushi⁹,Yoshizawa Takahiro¹⁰,Saiki Masafumi¹¹,Tambo Yuichi¹²,Koyama Junji¹³,Kanazu Masaki¹⁴^ORCID,Kudo Keita¹⁵,Tsuchiya‐Kawano Yuko¹⁶,Yanagitani Noriko²,Nishio Makoto²^ORCID

Affiliation:

1. Department of Respiratory Medicine Osaka Red Cross Hospital Osaka Japan

2. Department of Thoracic Medical Oncology The Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan

3. Department of Respiratory Medicine Hirosaki University Graduate School of Medicine Hirosaki Japan

4. Department of Respiratory Medicine Tohoku University Hospital Sendai Japan

5. Department of Pulmonary Medicine Sendai Kousei Hospital Sendai Japan

6. Department of Respiratory Medicine Saitama Cancer Center Saitama Japan

7. Department of Pulmonary Medicine and Oncology Graduate School of Medicine, Nippon Medical School Tokyo Japan

8. Division of Respiratory NTT Medical Center Tokyo Japan

9. Division of Medical Oncology, Department of Medicine Showa University School of Medicine Tokyo Japan

10. Department of Respiratory Medicine Toho University School of Medicine Tokyo Japan

11. Department of Respiratory Medicine Graduate School of Medicine University of Yamanashi Yamanashi Japan

12. Department of Respiratory Medicine Kanazawa University Kanazawa Japan

13. Department of Respiratory Medicine Nagoya University Graduate School of Medicine Nagoya Japan

14. Department of Thoracic Oncology National Hospital Organization Osaka Toneyama Medical Center Osaka Japan

15. Department of Medical Oncology and Respiratory Medicine National Hospital Organization Osaka Minami Medical Center Osaka Japan

16. Department of Respiratory Medicine Kitakyushu Municipal Medical Center Kitakyushu Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14729

Reference31 articles.

1. What's New in SCLC? A Review

2. Current standards for clinical management of small cell lung cancer

3. Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

4. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

5. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors;Cancer Medicine;2024-04

2. A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment;Journal of Thoracic Oncology;2024-02

3. Metastatic small cell bladder cancer treated with sequential systemic therapy including pembrolizumab and amrubicin: A case report;IJU Case Reports;2023-12-19

4. Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy;Journal of Thoracic Oncology;2023-09

5. Extensive-Stage Small-Cell Lung Cancer: Current Landscape and Future Prospects;OncoTargets and Therapy;2023-08